Allogene Therapeutics (ALLO) Leases (2019 - 2025)
Historic Leases for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $40.9 million.
- Allogene Therapeutics' Leases rose 22488.1% to $40.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.9 million, marking a year-over-year increase of 22488.1%. This contributed to the annual value of $45.2 million for FY2024, which is 2903.79% down from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Leases is $40.9 million, which was up 22488.1% from $42.0 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Leases registered a high of $86.8 million during Q2 2022, and its lowest value of $7.5 million during Q2 2024.
- Over the past 5 years, Allogene Therapeutics' median Leases value was $57.1 million (recorded in 2022), while the average stood at $55.3 million.
- Its Leases has fluctuated over the past 5 years, first skyrocketed by 4008900.0% in 2021, then plummeted by 9066.17% in 2024.
- Quarter analysis of 5 years shows Allogene Therapeutics' Leases stood at $58.0 million in 2021, then surged by 44.05% to $83.6 million in 2022, then dropped by 23.79% to $63.7 million in 2023, then dropped by 29.04% to $45.2 million in 2024, then decreased by 9.45% to $40.9 million in 2025.
- Its Leases stands at $40.9 million for Q3 2025, versus $42.0 million for Q2 2025 and $44.1 million for Q1 2025.